Literature DB >> 18402982

Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins.

Masaki Kobayashi1, Ikumi Chisaki, Katsuya Narumi, Kazuhiro Hidaka, Toshiki Kagawa, Shirou Itagaki, Takeshi Hirano, Ken Iseki.   

Abstract

In the present study, we examined the mechanisms underlying the cytotoxicity of pitavastatin, a new statin, and we compared the in vitro potencies of muscle cytotoxicity using a prototypic embryonal rhabdomyosarcoma cell line (RD cells), a typical side effect of statins and compared the cholesterol-lowering effects of statins using Hep G2 hepatoma cells. Pitavastatin reduced the number of viable cells and caused caspase-9 and -3/7 activation in a time- and concentration-dependent manner. The comparison of cytotoxities of statins showed that statins significantly reduced cell viability and markedly enhanced activity of caspase-3/7 in concentration-dependent manner. On the other hand, the effects of hydrophilic statins, pravastatin, rosuvastatin were very weak. The rank order of cytotoxicity was cerivastatin > simvastatin acid> fluvastatin > atorvastatin > lovastatin acid > pitavastatin >> rosuvastatin, pravastatin. Statin-induced cytotoxicity is associated with these partition coefficients. On the other hand, the cholesterol-lowering effect of statins did not correlate with these partition coefficients and cytotoxicity. Thus, it is necessary to consider the association between risk of myopathy and cholesterol-lowering effect of a statin for precise use of statins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18402982     DOI: 10.1016/j.lfs.2008.02.019

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  20 in total

Review 1.  The effects of statin medications on aerobic exercise capacity and training adaptations.

Authors:  Zsolt Murlasits; Zsolt Radák
Journal:  Sports Med       Date:  2014-11       Impact factor: 11.136

Review 2.  Effects of statins on skeletal muscle: a perspective for physical therapists.

Authors:  Stephanie L Di Stasi; Toran D MacLeod; Joshua D Winters; Stuart A Binder-Macleod
Journal:  Phys Ther       Date:  2010-08-05

3.  Serum myoglobin in patients with thyroid dysfunction.

Authors:  Waad-Allah S Mula-Abed; Sawsan S Al-Sinani; Huda S Al-Hashmi
Journal:  Sultan Qaboos Univ Med J       Date:  2009-03-16

4.  Rosuvastatin Nanomicelles Target Neuroinflammation and Improve Neurological Deficit in a Mouse Model of Intracerebral Hemorrhage.

Authors:  Liu Zi; Wencheng Zhou; Jiake Xu; Junshu Li; Ning Li; Jianguo Xu; Chao You; Chengwei Wang; Meng Tian
Journal:  Int J Nanomedicine       Date:  2021-04-20

5.  A mechanistic, model-based approach to safety assessment in clinical development.

Authors:  J Lippert; M Brosch; O von Kampen; M Meyer; H-U Siegmund; C Schafmayer; T Becker; B Laffert; L Görlitz; S Schreiber; P J Neuvonen; M Niemi; J Hampe; L Kuepfer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-11-07

6.  β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats.

Authors:  Ederlan S Ferreira; Maraiza A Silva; Aureluce Demonte; Valdir A Neves
Journal:  Lipids Health Dis       Date:  2012-01-13       Impact factor: 3.876

7.  Hypocholesterolaemic effect of rat-administered oral doses of the isolated 7S globulins from cowpeas and adzuki beans.

Authors:  Ederlan S Ferreira; Ana Lucia S Amaral; Aureluce Demonte; Cleslei F Zanelli; Jessica Capraro; Marcello Duranti; Valdir A Neves
Journal:  J Nutr Sci       Date:  2015-02-16

8.  SLCO1B1 Polymorphisms and Statin-Induced Myopathy.

Authors:  Alison Stewart
Journal:  PLoS Curr       Date:  2013-12-04

9.  Effects of long-term atorvastatin treatment on cardiac aging.

Authors:  Lei Han; Minggao Li; Xin Liu
Journal:  Exp Ther Med       Date:  2013-07-05       Impact factor: 2.447

10.  Daptomycin in combination with rosuvastatin induced blood creatine phosphokinase elevation.

Authors:  Mefküre Durmuş; Ömer Faruk Bahçecioğlu; Selim Gök
Journal:  Eur J Hosp Pharm       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.